or Try an Advanced Search...

    Nephritis Stocks List

    Symbol Grade Name % Change
    BIIB C Biogen Idec Inc. -1.84
    AUPH D Aurinia Pharmaceuticals Inc 0.74
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Immunosuppressants Lupus Lupus Nephritis Medicine Alzheimer's Disease Autoimmune Disease Autoimmune Disorders Biopharmaceutical Biotechnology Cd20 Chronic Lymphocytic Leukemia Clinical Development Clinical Trial Product Clinical Trial Products Degenerative Disease Disability Drugs Hemophilia Idiopathic Pulmonary Fibrosis Immune Disorders

    Related ETFs - A few ETFs which own one or more of the above listed Nephritis stocks.

    Symbol Grade Name Weight
    BIS D ProShares UltraShort Nasdaq Biotechnology 6.12
    MNTL B Tema Neuroscience and Mental Health ETF 4.68
    BBH B Market Vectors Biotech ETF 4.41
    IBRN D iShares Neuroscience and Healthcare ETF 3.99
    MVAL D SHL Telemedicine Ltd VanEck Morningstar Wide Moat Value ETF 3.88
    View all Nephritis ETFs...
    Compare ETFs
    Compare BBH to MVAL Compare BIS to BBH Compare BIS to MNTL

        Nephritis Stocks Recent News

        Date Stock Title
        Jul 3 BIIB Top Stock Movers Now: Tesla, Paramount Global, Biogen, and More
        Jul 3 BIIB Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
        Jul 2 BIIB Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug
        Jul 2 BIIB US Equities Markets End Higher Tuesday Following Fed Chair Powell's Comments
        Jul 2 BIIB Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth
        Jul 2 BIIB Biogen Completes Acquisition of Human Immunology Biosciences
        Jul 1 BIIB 10 clinical trials to watch in the second half of 2024
        Jun 28 AUPH Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) most popular amongst retail investors who own 54% of the shares, institutions hold 35%
        Jun 28 BIIB Biogen, Eisai launch Alzheimer's drug Leqembi in China
        Jun 28 BIIB Eisai and Biogen launch LEQEMBI for Alzheimer’s in China
        Jun 28 BIIB Eisai and Biogen launch Alzheimer's drug Leqembi in China
        Jun 27 BIIB “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Immunosuppressants Lupus Lupus Nephritis Medicine Alzheimer's Disease Autoimmune Disease Autoimmune Disorders Biopharmaceutical Biotechnology Cd20 Chronic Lymphocytic Leukemia Clinical Development Clinical Trial Product Clinical Trial Products Degenerative Disease Disability Drugs Hemophilia Idiopathic Pulmonary Fibrosis Immune Disorders
        Nephritis

        Nephritis is inflammation of the kidneys and may involve the glomeruli, tubules, or interstitial tissue surrounding the glomeruli and tubules.

        More about Nephritis
        Browse All Tags